Nepafenac loaded ophthalmic nanocarriers for treatment of uveitis: A review
Department of Quality Assurance, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur (M.S)-441002, India.
Review Article
GSC Biological and Pharmaceutical Sciences, 2021, 15(03), 154–163.
Article DOI: 10.30574/gscbps.2021.15.3.0153
Publication history:
Received on 30 April 2021; revised on 01 June 2021; accepted on 06 June 2021
Abstract:
Visual impairment (VI), a worldwide worry that is probably going to raise with delayed futures, has gained increasing attention in the domain of eye care. Now a days, new cases of visual impairment occur in older individuals, some children are born with visual impairments resulting from retinopathy of prematurity, a condition associated with premature birth. Other children experience vision loss because of congenital glaucoma or congenital cataracts, Uveitis and some experience vision loss of unknown etiology. Uveitis is an intraocular inflammation involving primarily the uveal tract. Vision is one of our most cherished senses. There are nearly 45 million people worldwide who are blind and a further 135 million people are visually disabled. Uveitis causes 0.6% - 11% of blindness in various studies. The ophthalmic preparations are available as buffered, sterile and isotonic solution. For the ocular delivery of drugs, several types of dosage forms are prepared and marketed. As drops are easier to administer so the most prescribed dosage form is the eye drop solution. Nepafenac is unique among ophthalmic NSAIDs in that it is a prodrug deaminated to amfenac, a highly effective non-selective cyclooxygenase inhibitor. The compiled data presented in this review will act as a good information resource and reference point for further research in the field of ocular drug delivery aiming non-invasive sustained release of drugs in the anterior and posterior segments of the eye.
Keywords:
Ocular drug delivery; Uveitis; Nepafenac; Nanomicelles
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
